eligibility_summary
Eligible: consented pts (age >=1) ineligible for commercial CAR-T, with haploidentical family donor, relapsed/refractory mature B-cell malignancy (e.g., FL, MZL, DLBCL/PMBL/HGBCL, MCL, CLL/LL), >=2 prior lines, measurable/assessable disease, ECOG <=2/Lansky>50, life expectancy >12 wks, adequate cardiac/pulmonary, liver, renal, marrow, contraception. Exclude: active serious infection, uncontrolled HBV/HCV, CNS lymphoma, rapid disease, recent major surgery/therapy/SCT, active GvHD, recent CAR-T, significant comorbidity, high steroids, live vaccine.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CARCIK-CD19—an allogeneic, gene-modified cellular immunotherapy. Donor peripheral-blood T cells (at least haploidentical) are differentiated via the cytokine-induced killer (CIK) protocol (predominantly CD3+CD8+, with some CD4/CD56), then transduced using a transposon to express a CD19-targeted chimeric antigen receptor. The CAR comprises an anti-CD19 scFv linked to CD3 zeta signaling plus tandem costimulatory domains CD28 and OX40. Mechanism: CAR engagement of CD19 on B cells triggers CD3z/CD28/OX40 signaling, activating cytotoxic effector functions and proliferation of CIK-derived T/NK-like cells to eliminate malignant CD19+ B cells. Targets: CD19 on normal and malignant B cells, intracellular T-cell activation and costimulatory pathways (CD3z, CD28, OX40). Indications: relapsed/refractory B-cell NHL and CLL. Phase I/II, single-arm.